STAT+: ‘’This is unprecedented’: Several private insurers won’t cover Biogen’s Alzheimer’s drug

At least half-a-dozen private health insurers in some of the nation’s largest states are balking at covering Biogen’s controversial drug for Alzheimer’s disease, saying it is an experimental and unproven treatment despite being approved by the federal government one month ago.

Six affiliates of Blue Cross and Blue Shield in Florida, New York, Michigan, North Carolina, and Pennsylvania say in newly adopted policies they will not cover the Cambridge biotech’s drug, Aduhelm, because they consider it “investigational” or “experimental” or because “a clinical benefit has not been established.” Aduhelm, which is priced at $56,000 a year, is intended to slow cognitive decline in patients with early Alzheimer’s symptoms, regardless of their age.

Continue to STAT+ to read the full story…

STAT+: ‘’This is unprecedented’: Several private insurers won’t cover Biogen’s Alzheimer’s drug

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top